Biogen
BIIB
886 hedge funds and large institutions have $17.8B invested in Biogen in 2025 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 334 increasing their positions, 275 reducing their positions, and 108 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 334 | Existing positions reduced: 275
1% more funds holding
Funds holding: 879 → 886 (+7)
2% less first-time investments, than exits
New positions opened: 106 | Existing positions closed: 108
1.97% less ownership
Funds ownership: 90.76% → 88.78% (-2%)
22% less capital inflows, than outflows
Capital inflows: $1.47B | Capital outflows: $1.87B
44% less call options, than puts
Call options by funds: $345M | Put options by funds: $621M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$119M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$106M |
| 3 |
SG Americas Securities
New York
|
+$103M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$58.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
-$250M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$188M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$112M |
| 4 |
JP Morgan Chase
New York
|
-$90.4M |
| 5 |
OrbiMed
New York
|
-$77.9M |
BIIB Hedge Fund Activity: Q1 2025 in Review
886 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2025, worth a combined $17.8B — down 12% from $20.2B a quarter earlier.
Sellers outnumbered buyers: 108 funds closed out of BIIB and 106 opened new positions — a net loss of 2 holders — while 275 trimmed existing stakes and 334 added.
The largest buyer was AQR Capital Management, adding an estimated $119M. The largest seller was Beutel, Goodman & Co, cutting an estimated $250M.
- 886 institutional investors held Biogen (BIIB) as of Q1 2025, up from 879 in Q4 2024.
- Funds reported $17.8B of Biogen stock for Q1 2025, down 12% quarter-over-quarter.
- 106 funds opened new Biogen positions in Q1 2025 and 108 closed out, a net change of -2 holders.
- The largest Biogen buyer in Q1 2025 was AQR Capital Management, an estimated $119M added.
- The largest Biogen seller in Q1 2025 was Beutel, Goodman & Co, an estimated $250M sold.
Based on aggregated 13F filings for Q1 2025.